Infex Therapeutics begins Phase IIa trial for RESP-X in NCFB patients

SalioGen Therapeutics names new chief medical officer

Destiny Pharma launches research on XF-73 for cystic fibrosis MRSA infections

Polarean Imaging enters into trade-in agreement with University of Kansas Medical Center

Avidity Biosciences announces positive initial AOC 1020 data from the Phase 1/2 FORTITUDE trial in facioscapulohumeral muscular dystrophy

Intellia Therapeutics and ReCode Therapeutics join forces for gene editing therapies in cystic fibrosis

Sionna Therapeutics doses first healthy subject in SION-109 phase one clinical trial

Arcturus Therapeutics granted FDA Orphan Drug Designation for ARCT-032 to treat cystic fibrosis

SpliSense completes SPL84 first-in-human, Phase one clinical trial for cystic fibrosis treatment

Alcresta Therapeutics' RELiZORB (iMMOBILIZED LIPASE) cartridge receives FDA expanded use clearance for paediatric patients aged 2 to 5 years

Positive Phase 2, Proof-of-Concept Results for VX-548 Published in New England Journal of Medicine

Inogen acquires Physio-Assist, expanding respiratory product portfolio and global presence

Vertex Pharmaceuticals receives European Commission approval for ORKAMBI (lumacaftor/ivacaftor) To treat children with cystic fibrosis aged 1 to <2 years old

cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial

Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment with CFTR Modulators at the European Cystic Fibrosis Conference